UWCCC uses the CCSG Protocol Specific Research (PSR) support for member's pilot clinical and/or translational research studies that would benefit from timely funding. CCSG PSR funding supports the translation of UWCCC research originating from novel laboratory or clinical observations into clinical testing. UWCCC Scientific Programs support the translation and facilitation of these research ideas into the clinic. In addition to benefiting UWCCC through investigator-initiated research efforts for the local community of cancer patients, this funding mechanism also benefits our Wisconsin Oncology Network (WON) by allowing more rapid dissemination of novel cancer therapies throughout the state of Wisconsin. UWCCC Scientific Programs conducting clinical research such as Experimental Therapeutics or Imaging and Radiation Sciences provide structure for clinical research. This has resulted in disease groups having research nurse and data management staff adequate for the conduct of ongoing trials. However the extent of resources available to each group does vary. Therefore, UWCCC provides additional support for short term, feasibility and Phase I clinical trials originating from scientific investigators within UWCCC. Through UWCCC Data and Safety Monitoring System, oversight, auditing and monitoring for all clinical trials is accomplished. In addition, the OnCore database supports these clinical trials assuring data are accurately, timely and completely captured in the database. Criteria for support of these clinical trials are as follows: ? Trial should be high priority, innovative, feasibility (pre Phase I, pilot) and Phase I institutional clinical interventions focusing on initial early phase testing of a candidate agent or device for diagnosis, prevention, detection, or treatment of cancer. Support is not meant for all early phase I trials, for later phase trials, or for studies that do not involve testing of an agent or device. ? Trials must be conceptualize/designed by UWCCC members. ? Trials must be of short duration (likely one year or less.) ? Trials receiving support from other peer reviewed research grants, cooperative agreements, and contracts are ineligible. Trials may receive partial support from industry assuming all other criteria are met. ? Trials must be approved by UWCCC's PRMS. ? Funding is restricted to research nurses and data managers directly involved trial conduct.

Public Health Relevance

The PSR funds allocated each year are applied to investigator-initiated short term, feasibility and Phase I clinical trials to support the efforts of research nurses and data managers for these projects. The PSR mechanism provides critical support for the growing volume and diversity of scientifically novel investigator initiated clinical research at UWCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762777
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$101,057
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Pleiman, Jennifer K; Irving, Amy A; Wang, Zhishi et al. (2018) The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer. PLoS Genet 14:e1007611
Kletzien, Heidi; Macdonald, Cameron L; Orne, Jason et al. (2018) Comparison Between Patient-Perceived Voice Changes and Quantitative Voice Measures in the First Postoperative Year After Thyroidectomy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 144:995-1003
Kang, Lei; Jiang, Dawei; Ehlerding, Emily B et al. (2018) Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Mol Pharm 15:1627-1634
Bulu, Hakan; Sippo, Dorothy A; Lee, Janie M et al. (2018) Proposing New RadLex Terms by Analyzing Free-Text Mammography Reports. J Digit Imaging 31:596-603
Jewett, Patricia I; Gangnon, Ronald E; Elkin, Elena et al. (2018) Geographic access to mammography facilities and frequency of mammography screening. Ann Epidemiol 28:65-71.e2
Albertini, Mark R (2018) The age of enlightenment in melanoma immunotherapy. J Immunother Cancer 6:80
Shull, James D; Dennison, Kirsten L; Chack, Aaron C et al. (2018) Rat models of 17?-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention. Physiol Genomics 50:215-234
Kang, Lei; Jiang, Dawei; England, Christopher G et al. (2018) ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging 45:1372-1381
Melgar-Asensio, Ignacio; Kandela, Irawati; Aird, Fraser et al. (2018) Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging. Invest Ophthalmol Vis Sci 59:4071-4081
Jang, Samuel; Rosenberg, Stephen A; Hullet, Craig et al. (2018) Value of Elective Radiation Oncology Rotations: How Many Is Too Many? Int J Radiat Oncol Biol Phys 100:558-559

Showing the most recent 10 out of 1528 publications